Related Experiment Video
Updated: Jun 2, 2026
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Managing Prostate Cancer During [177Lu]Lu-PSMA-617 Radioligand Therapy: Tips for Oncology Nurses
1Avery Spitz.
Background:
Radioligand therapy (RLT), particularly lutetium 177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 is an approved targeted treatment for metastatic castration-resistant prostate cancer.
Objectives:
This article aims to equip oncology nurses with essential knowledge about and strategies for managing patients with prostate cancer undergoing [177Lu]Lu-PSMA-617 RLT.
Methods:
RLT is associated with low-grade and self-limited toxicities, such as fatigue, xerostomia, and nausea. Reviewing the literature and real-world clinical experience, nurses can learn to support patients in the outpatient setting.
Findings:
Nurses should focus on patient selection, management of preexisting conditions, and supportive care strategies to mitigate common side effects. Nurses should monitor blood counts, prostate-specific antigen levels, and renal function throughout treatment cycles. Patient education about post-therapy radiation safety and waste disposal ensures safe home environments.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...